Key Points
- Eric Venker sold 200,000 shares on Jan. 12 at $21.92 (≈$4.38M) and has disposed of about 1.31M shares in recent months for roughly $26.2M, reducing his stake by ~10.8%; he now directly owns 1,654,597 shares (~$36.27M).
- Roivant stock is trading near its 12‑month high (opened $23.81) with a $16.56B market cap, and analyst sentiment is broadly positive—consensus rating "Moderate Buy" with an average price target of $25.19.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $21.92, for a total value of $4,384,000.00. Following the sale, the chief executive officer directly owned 1,654,597 shares of the company's stock, valued at approximately $36,268,766.24. This trade represents a 10.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Eric Venker also recently made the following trade(s):
- On Wednesday, December 24th, Eric Venker sold 75,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.53, for a total value of $1,689,750.00.
- On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $22.45, for a total value of $4,490,000.00.
- On Tuesday, December 9th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.85, for a total transaction of $4,170,000.00.
- On Friday, November 7th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.22, for a total transaction of $4,044,000.00.
- On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The shares were sold at an average price of $17.06, for a total transaction of $2,020,211.08.
- On Thursday, October 16th, Eric Venker sold 318,282 shares of Roivant Sciences stock. The stock was sold at an average price of $17.05, for a total transaction of $5,426,708.10.
Roivant Sciences Stock Up 1.6%
Roivant Sciences stock opened at $23.81 on Thursday. The firm has a fifty day simple moving average of $21.40 and a two-hundred day simple moving average of $16.46. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $23.83. The company has a market capitalization of $16.56 billion, a PE ratio of -42.52 and a beta of 1.22.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the company. Wall Street Zen raised Roivant Sciences from a "strong sell" rating to a "hold" rating in a research note on Sunday, November 16th. HC Wainwright raised their target price on shares of Roivant Sciences from $23.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, December 12th. JPMorgan Chase & Co. upped their price target on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an "overweight" rating in a report on Thursday, September 18th. Leerink Partners increased their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, December 15th. Finally, The Goldman Sachs Group boosted their price objective on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a "buy" rating in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Roivant Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $25.19.
Read Our Latest Report on Roivant Sciences
Institutional Trading of Roivant Sciences
Several large investors have recently added to or reduced their stakes in the stock. Rubric Capital Management LP raised its holdings in Roivant Sciences by 14.7% in the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company's stock worth $229,574,000 after purchasing an additional 2,603,260 shares in the last quarter. State Street Corp increased its position in shares of Roivant Sciences by 4.8% during the second quarter. State Street Corp now owns 19,773,480 shares of the company's stock valued at $222,847,000 after buying an additional 911,827 shares during the period. Two Seas Capital LP raised its stake in Roivant Sciences by 4.6% in the second quarter. Two Seas Capital LP now owns 10,598,040 shares of the company's stock worth $119,440,000 after buying an additional 461,733 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Roivant Sciences by 18.0% in the third quarter. Dimensional Fund Advisors LP now owns 9,308,710 shares of the company's stock worth $140,839,000 after buying an additional 1,423,074 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in Roivant Sciences by 11,507.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company's stock worth $150,535,000 after buying an additional 6,877,348 shares during the period. Institutional investors own 64.76% of the company's stock.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
